We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Three acute treatments for migraine — Eli Lilly’s Reyvow (lasmiditan), Biohaven’s rimegepant, and Allergan’s Ubrelvy (ubrogepant) — may not be cost-effective, according to the Institute for Clinical and Economic Review (ICER). Read More
Biogen has agreed to purchase Pfizer’s early-stage neurological disease drug for $75 million plus royalties and up to $635 million in future payments. The acquisition of PF-05251749 marks the latest move by Biogen into potential treatments for neurological diseases. Read More
The European Commission has approved AbbVie’s $63 billion acquisition of Allergan on condition that the companies sell off Allergan’s investigational treatment for inflammatory bowel disease (IBD). Read More
The FDA hit a Rockledge, Florida over-the-counter drugmaker with a warning letter over failures related to testing, quality unit oversight and water quality monitoring. Read More
A bipartisan drug pricing bill currently awaiting a vote on the Senate floor could have unintended consequences for generics, according to the Association for Accessible Medicines. Read More
Bristol-Myers Squibb and Sanofi have filed a complaint against the state of Hawaii over a lawsuit that seeks massive fines against the drugmakers for failing to include a warning in labeling for their anti-blood clotting drug Plavix (clopidogrel). Read More
The EMA authorized fewer new active substances and orphan drugs in 2019 than in the previous year, according to the agency’s highlights released yesterday. Read More